Applications of 1-Phenyl-1H-Pyrazole-4-Carboxylic Acid in Industrial Manufacturing

1-Phenyl-1H-Pyrazole-4-Carboxylic Acid serves as a crucial intermediate in several high-value sectors with clearly defined regulatory boundaries. As an original manufacturer, we deliver consistent quality for downstream supply chains, supporting efficiency in synthesis, precise formulation, and integration in specialized production lines.

1. Active Ingredient Intermediate for Selective Herbicides

Producers of leading commercial herbicides deploy this compound as a core building block when synthesizing pyrazole-based active ingredients. Adherence to agrochemical safety and traceability systems, alongside batch consistency, remains essential throughout multi-stage preparations, all while optimizing overall yield and final actives’ purity.

Industry compliance standards

• FAO Specification for Plant Protection Products
• ISO 17025 Laboratory Accreditation (agrochemical analysis)
• REACH Regulation (EC) No 1907/2006 for chemical register and documentation
• OECD Principles of Good Laboratory Practice (GLP)

Typical usage ratio

• 5–20% by mole as a raw substrate in the initial condensation or cyclization step; actual charge rate optimized relative to co-reactant and target yield for downstream sulfonylurea or triazole herbicide synthesis

Downstream process integration

• Introduced at the heterocyclization or coupling stage for ring-closure, prior to further derivatization (e.g., sulfonation, amidation, or alkylation); added to the reaction mix following calibrations based on in-process QC titration

Final product types

• Commercial weed control formulations for cereals, corn, and specialty crops (e.g., pyrazole-sulfonylurea actives)
• Water-dispersible granules and suspension concentrates for pre- and post-emergence field application

2. Pharmaceutical Intermediate for Antifungal Agents

This compound has a proven role in the multi-stage synthesis of azole antifungal agents, targeted at both human and veterinary finished drugs. Manufacturers focus on pharmaceutical-grade purity, with tight control over trace impurities and synthesis efficiency to meet global medicinal export requirements.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP/NF and European Pharmacopoeia monographs relevant to APIs
• 21 CFR Part 211 (U.S. FDA cGMP for finished pharmaceuticals)
• EDQM (European Directorate for the Quality of Medicines & HealthCare) GMP

Typical usage ratio

• 2–8% by mass, introduced as a pyrazole-4-carboxyl precursor; adjusted based on stoichiometric requirements and yield needs for each synthesis batch

Downstream process integration

• Charged at an intermediate step during multi-component condensation or selective chlorination, preceding downstream ring modifications and salt formation for final drug substance stage

Final product types

• Oral and intravenous antifungal APIs (e.g., pyrazole-azole hybrid molecules)
• Veterinary antifungal preparations in solid dose or injectable form

3. Intermediate in Synthesis of Advanced Agrochemical Fungicides

Advanced crop protection products utilize this material in synthesizing new-generation fungicides. Downstream formulators depend on supply purity and performance consistency, since reliability at this step impacts the activity spectrum and resistance management of market-facing products.

Industry compliance standards

• Regulation (EC) No 1107/2009 (EU Plant Protection Products Authorization)
• United States EPA Pesticide Registration Manual, Chemistry Requirements
• ISO 9001:2015 Quality Management in Agrochemical Production
• GLP-certified process documentation for intermediate synthesis

Typical usage ratio

• 4–15% per batch mass, matching downstream site requirements for scale and specific pyrazole moieties; ratio selected based on downstream conversion efficiency

Downstream process integration

• Fed during condensation with chlorinated aromatics or thio-ethers, in jacketed reactors with real-time monitoring to minimize byproduct formation prior to coupling and granulation

Final product types

• Systemic fungicide technicals for cereals, fruits, and vegetables (e.g., mixture-ready granules)
• Wettable powders and spray emulsions for broad-acre use

4. Building Block for Specialty Dyestuff Synthesis

Colorants for textiles and high-performance inks leverage this material’s aromatic scaffold in the creation of highly stable, lightfast dyes. Downstream dye makers rely on its structure to introduce pyrazole rings conferring specific color attributes and chemical robustness, supporting advanced textile compliance needs.

Industry compliance standards

• Oeko-Tex Standard 100—Certification requirements for harmful substances in dyes
• ZDHC MRSL (Manufacturing Restricted Substances List) for textile inputs
• ISO 105 (Textile Tests for Color Fastness)
• EU REACH Annex XVII for registration and restrictions related to textile chemicals

Typical usage ratio

• 5–12% per charge mass, subject to substrate loading and color depth specification in final dye molecule assembly

Downstream process integration

• Charged at the aromatic substitution or azo coupling phase within dye synthesis, facilitating subsequent sulfonation or metallization depending on target dye class

Final product types

• Reactive and disperse dyes for polyester and cellulose fibers
• Pigments for automotive coatings and specialty industrial inks

5. Intermediate in Pyrazole-Based API Synthesis for CNS Pharmaceuticals

This chemical acts as a targeted intermediate in small-molecule syntheses directed at CNS (central nervous system) drug research and commercial scale-up. Pharmaceutical production sites employ it under tightly monitored conditions to ensure high selectivity, minimize process impurities, and allow full traceability for regulatory filings.

Industry compliance standards

• CGMP for Pharmaceuticals (China, US, EU—CFDA/FDA/EMA)
• ICH Q11 (Development and Manufacture of Drug Substances)
• Good Laboratory Practice (GLP) for preclinical intermediates
• ISO 13485 (for medical device-related pharmaceutical chemicals, where applicable)

Typical usage ratio

• 3–10% by weight, dosage determined by downstream synthetic route and yield maximization protocols for each CNS-targeting molecule

Downstream process integration

• Incorporated at substructure assembly stages via condensation or amidation, followed by purification and multistep transformation into the finished CNS-active agent

Final product types

• Oral tablets and capsules for neurological disorder treatment (pyrazole-substituted actives)
• Pilot and commercial scale research compounds for CNS clinical trials